The risk and outcomes of pneumonia in patients on inhaled corticosteroids

Oriol Sibila, Natalia Soto-Gomez, Marcos Restrepo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and asthma. ICS are associated with a decrease in exacerbations and improved quality of life in COPD, however multiple studies have linked the chronic use of ICSs with an increased risk of developing pneumonia, though the effect on mortality is unclear. We review the association of ICS with the risk of pneumonia and the implications on clinical outcomes.

Original languageEnglish (US)
Pages (from-to)130-136
Number of pages7
JournalPulmonary Pharmacology and Therapeutics
Volume32
DOIs
StatePublished - Jun 1 2015

Fingerprint

Pneumonia
Adrenal Cortex Hormones
Pulmonary diseases
Chronic Obstructive Pulmonary Disease
Anti-Inflammatory Agents
Asthma
Quality of Life
Mortality

Keywords

  • Chronic obstructive pulmonary disease
  • Inhaled corticosteroids
  • Pneumonia

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)
  • Biochemistry, medical

Cite this

The risk and outcomes of pneumonia in patients on inhaled corticosteroids. / Sibila, Oriol; Soto-Gomez, Natalia; Restrepo, Marcos.

In: Pulmonary Pharmacology and Therapeutics, Vol. 32, 01.06.2015, p. 130-136.

Research output: Contribution to journalArticle

@article{d94b2083d25844ecb6046c9687412948,
title = "The risk and outcomes of pneumonia in patients on inhaled corticosteroids",
abstract = "Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and asthma. ICS are associated with a decrease in exacerbations and improved quality of life in COPD, however multiple studies have linked the chronic use of ICSs with an increased risk of developing pneumonia, though the effect on mortality is unclear. We review the association of ICS with the risk of pneumonia and the implications on clinical outcomes.",
keywords = "Chronic obstructive pulmonary disease, Inhaled corticosteroids, Pneumonia",
author = "Oriol Sibila and Natalia Soto-Gomez and Marcos Restrepo",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.pupt.2015.04.001",
language = "English (US)",
volume = "32",
pages = "130--136",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - The risk and outcomes of pneumonia in patients on inhaled corticosteroids

AU - Sibila, Oriol

AU - Soto-Gomez, Natalia

AU - Restrepo, Marcos

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and asthma. ICS are associated with a decrease in exacerbations and improved quality of life in COPD, however multiple studies have linked the chronic use of ICSs with an increased risk of developing pneumonia, though the effect on mortality is unclear. We review the association of ICS with the risk of pneumonia and the implications on clinical outcomes.

AB - Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and asthma. ICS are associated with a decrease in exacerbations and improved quality of life in COPD, however multiple studies have linked the chronic use of ICSs with an increased risk of developing pneumonia, though the effect on mortality is unclear. We review the association of ICS with the risk of pneumonia and the implications on clinical outcomes.

KW - Chronic obstructive pulmonary disease

KW - Inhaled corticosteroids

KW - Pneumonia

UR - http://www.scopus.com/inward/record.url?scp=84930509134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930509134&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2015.04.001

DO - 10.1016/j.pupt.2015.04.001

M3 - Article

VL - 32

SP - 130

EP - 136

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

ER -